Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.67 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.67 |
| ▸ | TAS1R2 | Q8TE23 | 4/20 | 0.67 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4712243 | 1.00 | TAS1R3 (0.67) | TAS1R3TAS1R1TAS1R2MTNR1AMTNR1B | |
| SCHEMBL29961639 | 1.00 | TAS1R3 (0.67) | TAS1R3TAS1R1TAS1R2MTNR1AMTNR1B | |
| SCHEMBL7445852 | 0.84 | TAS1R3 (0.48) | TAS1R3TAS1R1TAS1R2MTNR1AMTNR1B | |
| SCHEMBL2464634 | 0.84 | TAS1R3 (0.48) | TAS1R3TAS1R1TAS1R2MTNR1AMTNR1B | |
| SCHEMBL2466133 | 0.84 | TAS1R3 (0.48) | TAS1R3TAS1R1TAS1R2MTNR1AMTNR1B | |
| SCHEMBL2464636 | 0.84 | TAS1R3 (0.48) | TAS1R3TAS1R1TAS1R2MTNR1AMTNR1B | |
| SCHEMBL599611 | 0.84 | TAS1R3 (0.48) | TAS1R3TAS1R1TAS1R2MTNR1AMTNR1B | |
| SCHEMBL9854691 | 0.83 | MTNR1A (0.51) | TAS1R3TAS1R1TAS1R2MTNR1AMTNR1B | |
| SCHEMBL30368188 | 0.82 | TAS1R3 (0.61) | TAS1R3TAS1R1TAS1R2PDPK1ATM | |
| SCHEMBL25249453 | 0.82 | TAS1R3 (0.61) | TAS1R3TAS1R1TAS1R2PDPK1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12110302-B2 | Metal complex, intermediate, and preparation method and application thereof | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2024-10-08 | — | — | US | disclosed |
| EP-3865494-B1 | METAL COMPLEX, INTERMEDIATE, AND PREPARATION METHOD AND APPLICATION THEREOF | SHANGHAI INST ORGANIC CHEMISTRY CAS (CN) | 2024-07-24 | — | — | EP | disclosed |
| US-20230114794-A1 | METAL COMPLEX, INTERMEDIATE, AND PREPARATION METHOD AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2023-04-13 | — | — | US | disclosed |
| EP-3865494-A1 | METAL COMPLEX, INTERMEDIATE, AND PREPARATION METHOD AND APPLICATION THEREOF | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2021-08-18 | — | — | EP | disclosed |
| EP-3865494-A1 | METAL COMPLEX, INTERMEDIATE, AND PREPARATION METHOD AND APPLICATION THEREOF | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2021-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230114794-A1 | METAL COMPLEX, INTERMEDIATE, AND PREPARATION METHOD AND APPLICATION THEREOF | AP2M1, AP3M1, AP1M1 | TAS1R3 3325/4885TAS1R1 3236/4885TAS1R2 2953/4885 |
| US-12110302-B2 | Metal complex, intermediate, and preparation method and application thereof | AP2M1, AP3M1, AP1M1 | TAS1R3 3325/4885TAS1R1 3236/4885TAS1R2 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.